Search Results - "Daley, Brianna R"

SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma by Theard, Patricia L., Linke, Amanda J., Sealover, Nancy E., Daley, Brianna R., Yang, Johnny, Cox, Katherine, Kortum, Robert L.

“…Son of sevenless 1 and 2 (SOS1 and SOS2) are RAS guanine nucleotide exchange factors (RasGEFs) that mediate physiologic and pathologic receptor tyrosine kinase…”
Get full text

In situ modeling of acquired resistance to RTK/RAS-pathway-targeted therapies by Sealover, Nancy E., Theard, Patricia L., Hughes, Jacob M., Linke, Amanda J., Daley, Brianna R., Kortum, Robert L.

“…Intrinsic and acquired resistance limit the window of effectiveness for oncogene-targeted cancer therapies. Here, we describe an in situ resistance assay…”
Get full text

Protocol for modeling acquired resistance to targeted therapeutics in adherent and suspension cancer cell lines via in situ resistance assay by Sealover, Nancy E., Hughes, Jacob M., Theard, Patricia L., Chatterjee, Deepan, Linke, Amanda J., Finniff, Bridget A., Daley, Brianna R., Lewis, Robert E., Kortum, Robert L.

“…Acquired resistance to oncogene-targeted therapies is the major driver of mortality for patients with cancer. Here, we present a 6-to-16-week assay to model…”
Get full text

SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status by Daley, Brianna R, Vieira, Heidi M, Rao, Chaitra, Hughes, Jacob M, Beckley, Zaria M, Huisman, Dianna H, Chatterjee, Deepan, Sealover, Nancy E, Cox, Katherine, Askew, James W, Svoboda, Robert A, Fisher, Kurt W, Lewis, Robert E, Kortum, Robert L

“…KRAS is the most commonly mutated oncogene. Targeted therapies have been developed against mediators of key downstream signaling pathways, predominantly…”
Get full text

SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma by Daley, Brianna R, Sealover, Nancy E, Finniff, Bridget A, Hughes, Jacob M, Sheffels, Erin, Gerlach, Daniel, Hofmann, Marco H, Kostyrko, Kaja, LaMorte, Joseph P, Linke, Amanda, Beckley, Zaria, Frank, Andrew M, Lewis, Robert E, Wilkerson, Matthew D, Dalgard, Clifton, Kortum, Robert L

“…The clinical effectiveness of KRASG12C inhibitors (G12Ci) is limited both by intrinsic and acquired resistance, necessitating the development of combination…”
Get full text